Page 167 - Mployee Wellness Programs News Today

Takeda Pharmaceutical drug TAK-279 achieved the main goal of a mid-stage clinical trial in plaque psoriasis, setting the stage for Phase 3. The Japanese pharmaceutical giant sees the small molecule as complementary to its top-selling product, the blockbuster inflammatory bowel disorder drug Entyvio, and competitive against Bristol Myers Squibb's Sotyktu.

In healthcare, we need honest methodologies that accurately capture both the cost and complexity of specialty care and deliver a reliable ROI calculation. Only this sort of replicable, high-integrity ROI calculation can truly associate accessing high quality specialists with lower cost and better outcomes amidst today’s healthcare access and affordability crisis.

The Covid-19 pandemic has transformed the way we think of diagnostics in our daily lives. In a recent webinar, BD Vice President for Diagnostics Nikos Pavlidis spoke with a clinician and an epidemiologist where they shared their perspectives on how testing developments have changed the way we track respiratory illnesses.

New technologies thoughtfully implemented help providers reallocate time and deliver new value by aligning efforts with provider goals to enhance the experience for patients. Leveraging these new digital solutions allows clinicians to streamline lower-priority and non-clinical tasks, so they’re able to focus on bedside patient care.

Patricia Kelmar, healthcare campaigns director at the Public Interest Research Group, is an advocate for the No Surprises Act. But there's one thing that bothers her: the fact that providers can ask patients to waive their surprise billing protections, she said Tuesday when speaking at the AHIP Medicare, Medicaid, Duals and Commercial Markets Forum in Washington, D.C.

Pear Therapeutics isn’t meeting the commercialization goals for its prescription digital therapeutics, so it’s now seeking strategic alternatives for the business. Prospective buyers can pick up Pear’s FDA-cleared products for substance use disorder, opioid use disorder, and insomnia.

Enzo BioChem’s sale of its clinical lab business to Labcorp is the culmination of a monthslong strategic review. Meanwhile, diagnostics and lab testing giant Labcorp is in the middle of its own corporate shakeup as it readies its clinical trials business for a spinoff as a standalone, publicly traded company.

CMS put out a request for information in October about a CMS-led national provider directory that would allow patients to find and compare providers based on preferences like language and location. Alexandra Mugge, director and deputy chief health informatics officer of the Health Informatics and Interoperability Group at CMS, said there is stakeholder support for the national directory — if it's executed correctly.

Without a new set of tools that clinicians can access at the point of care, the availability of information from QHINs will increase provider burdens because they will struggle to find the information needed to evaluate a patient, take action, complete documentation, and move to the next patient.

Royalty Pharma’s milestone payment from the approval of Pfizer migraine drug Zavzpret stems from financing deals struck with the therapy's previous developer, Biohaven Pharmaceuticals. Royalty Pharma is also in line to receive royalty payments going beyond the next decade.